Cargando…

Methods to Predict and Lower the Risk of Prostate Cancer

Chemoprevention for prostate cancer (PCa) continues to generate interest from both physicians and the patient population. The goal of chemoprevention is to stop the malignant transformation of prostate cells into cancer. Multiple studies on different substances ranging from supplements to medical th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ercole, Barbara, Parekh, Dipen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720086/ https://www.ncbi.nlm.nih.gov/pubmed/21479345 http://dx.doi.org/10.1100/tsw.2011.72

Ejemplares similares

Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis
por: Fitzgerald, John P., et al.
Publicado: (2010)

Entering an era of radiogenomics in prostate cancer risk stratification
por: Soodana-Prakash, Nachiketh, et al.
Publicado: (2018)

Focal therapy for localized prostate cancer – Current status
por: Atluri, Shrikanth, et al.
Publicado: (2022)

Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise
por: Darwiche, Fadi, et al.
Publicado: (2015)

Multiparametric-MRI and Targeted Biopsies in the Management of Prostate Cancer Patients on Active Surveillance
por: Sandler, Kiri, et al.
Publicado: (2015)

Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer
por: Punnen, Sanoj, et al.
Publicado: (2018)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
por: Roobol, Monique J., et al.
Publicado: (2011)

Prostate cancer polygenic risk score and prediction of lethal prostate cancer
por: Klein, Robert J., et al.
Publicado: (2022)

A 4K score/MRI‐based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer
por: Wagaskar, Vinayak G., et al.
Publicado: (2021)

Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI
por: Stoyanova, Radka, et al.
Publicado: (2023)

Underlying Features of Prostate Cancer—Statistics, Risk Factors, and Emerging Methods for Its Diagnosis
por: Berenguer, Cristina V., et al.
Publicado: (2023)

Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis
por: Osses, Daniël F., et al.
Publicado: (2019)

Vitamins and Prostate Cancer Risk
por: Donkena, Krishna Vanaja, et al.
Publicado: (2010)

Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences
por: Chang, K-H, et al.
Publicado: (2014)

Prostate cancer risk prediction based on complete prostate cancer family history
por: Albright, Frederick, et al.
Publicado: (2015)

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
por: Parekh, Sneha, et al.
Publicado: (2022)

Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies
por: Stoyanova, Radka, et al.
Publicado: (2016)

Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank
por: Green, Harry D., et al.
Publicado: (2022)

Prostate cancer risk prediction using a polygenic risk score
por: Sipeky, Csilla, et al.
Publicado: (2020)

The Role of Single Nucleotide Polymorphisms in Predicting Prostate Cancer Risk and Therapeutic Decision Making
por: Van den Broeck, Thomas, et al.
Publicado: (2014)

Atypical ATMs: Broadening the phenotypic spectrum of ATM-associated hereditary cancer
por: Borja, Nicholas A., et al.
Publicado: (2023)

Clinical value of intravesical prostatic protrusion in the evaluation and management of prostatic and other lower urinary tract diseases
por: Mehraban, Darab
Publicado: (2017)

Transperineal Laser Ablation of the Prostate (TPLA) for Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction
por: Sessa, Francesco, et al.
Publicado: (2023)

Lower Urinary Tract Symptoms in Prostate Cancer Patients Treated With Radiation Therapy: Past and Present
por: Kwon, Whi-An, et al.
Publicado: (2021)

Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
por: Hwang, Taewon, et al.
Publicado: (2023)

Inflammatory Genetic Markers of Prostate Cancer Risk
por: Tindall, Elizabeth A., et al.
Publicado: (2010)

Defining risks and predicting adverse events after lower extremity bypass for critical limb ischemia
por: Siracuse, Jeffrey J, et al.
Publicado: (2014)

Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction
por: Ying, Mingshuai, et al.
Publicado: (2023)

Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention
por: Cavalieri, Ercole L., et al.
Publicado: (2016)

Risk-prediction tools in prostate cancer: the challenge of tailoring
por: Morlacco, Alessandro, et al.
Publicado: (2016)

Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele
por: Bentmar Holgersson, Magdalena, et al.
Publicado: (2017)

The 3,4-Quinones of Estrone and Estradiol Are the Initiators of Cancer whereas Resveratrol and N-acetylcysteine Are the Preventers
por: Cavalieri, Ercole, et al.
Publicado: (2021)

The Prevalence of Lower Limb and Genital Lymphedema after Prostate Cancer Treatment: A Systematic Review
por: Clinckaert, Andries, et al.
Publicado: (2022)

Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors
por: Parsons, J. Kellogg
Publicado: (2010)

miRNAs associated with prostate cancer risk and progression
por: Luu, Hung N., et al.
Publicado: (2017)

Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy
por: Falagario, Ugo Giovanni, et al.
Publicado: (2021)

Vitamin D, Sunlight and Prostate Cancer Risk
por: Donkena, Krishna Vanaja, et al.
Publicado: (2011)

Management of High-Risk Localized Prostate Cancer
por: Marciscano, Ariel E., et al.
Publicado: (2012)

Active surveillance for low-risk prostate cancer
por: Klotz, Laurence
Publicado: (2012)

Neoadjuvant Therapy in High-Risk Prostate Cancer
por: Ashrafi, Akbar N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2vhfv7t820q4e3oulfjqrbjgo5